Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect
Marketwatch
Mon, 07/22/19 - 10:15 am
Celgene
Biogen
AbbVie
Bristol-Myers Squibb
earnings
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
Yahoo/Zacks.com
Sun, 07/21/19 - 04:26 pm
Biogen
earnings
Threats to Spinraza are mounting, but Biogen still has cards to play
EP Vantage
Mon, 07/1/19 - 07:25 pm
Biogen
SMA
Spinraza
Novartis
Roche
risdiplam
Zolgensma
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Motley Fool
Tue, 06/18/19 - 11:54 am
Pfizer
Array Biopharma
M&A
Amgen
Gilead Sciences
Biogen
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Investors Business Daily
Sat, 06/15/19 - 05:44 pm
Alzheimer's disease
drug development
Biogen
Eisai
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Thu, 05/30/19 - 09:42 am
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
Scratch that: Biogen's board expansion hits snag as Catalent CEO John Chiminski drops out
Fierce Pharma
Tue, 05/28/19 - 11:50 am
Biogen
John Chiminski
Catalent
[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone
CP Wire
Tue, 05/28/19 - 10:26 am
life sciences
Source Explorer
Gilead Sciences
Roche
Mylan
Biogen
Genentech
AstraZeneca
[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone
Tue, 05/28/19 - 10:24 am
life sciences
Source Explorer
Gilead Sciences
Roche
Mylan
Biogen
Genentech
AstraZeneca
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Fri, 05/24/19 - 10:42 am
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Beleaguered Biogen faces the music as a chorus of critics push for a transformative approach to M&A
Endpoints
Tue, 05/21/19 - 09:30 am
Biogen
M&A
aducanumab
Credit Suisse
Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS
BioSpace
Wed, 05/15/19 - 11:43 pm
Biogen
tofersen
antisense
Ionis Pharmaceuticals
ALS
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Endpoints
Tue, 05/14/19 - 09:56 am
Alzheimer's disease
drug development
aducanumab
Biogen
Eisai
BAN2401
Merck
Eli Lilly
AstraZeneca
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Tue, 05/7/19 - 10:19 am
Roche
PTC Therapeutics
spinal muscular atrophy
risdiplam
Novartis
Zolgensma
Biogen
Spinraza
New Zolgensma data suggest comparable efficacy to Spinraza — analysts
Endpoints
Mon, 05/6/19 - 09:52 pm
Novartis
FDA
spinal muscular atrophy
Zolgensma
AveXis
Biogen
Spinraza
Eisai Continues Alzheimer's Research, Adds 2 Alzheimer's Pros as Execs
BioSpace
Sun, 05/5/19 - 10:36 am
Eisai
Biogen
Alzheimer's disease
R&D
aducanumab
BAN2401
After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug
NPR
Sat, 05/4/19 - 02:35 pm
Alzheimer's disease
R&D
drug development
beta amyloid
Biogen
Eisai
aducanumab
These 6 biotech stocks are promising takeover targets
Marketwatch
Thu, 05/2/19 - 11:33 am
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
Biogen CEO Vounatsos scores $2.5M raise amid investor demands for a new strategy
Fierce Pharma
Thu, 05/2/19 - 11:07 am
Biogen
Michel Vounatsos
executive pay
R&D
Biogen’s antisense ALS drug shows promise in early clinical trial
Fierce Biotech
Wed, 05/1/19 - 11:39 pm
Biogen
clinical trials
ALS
BIIB067
Pages
« first
‹ previous
…
26
27
28
29
30
31
32
33
34
…
next ›
last »